Abstract: The present invention discloses a novel fructophilic lactic acid producing bacteria Bacillus coagulans strain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria.

Abstract: The invention discloses novel intermediates in the synthesis of Calebin A represented by formula 3. The invention also covers processes for the synthesis of Calebin-A and its analogs using compounds of formula 3.

Abstract: The invention discloses compositions comprising bisdemethoxycurcumin and methods for managing polycystic ovary syndrome (PCOS) and its associated conditions which include hormonal imbalance, obesity, hypothyroidism, hyperandrogenism, oxidative stress, inflammation, gut dysbiosis, hypercholesterolemia, cardiovascular complications, hyperglycemia and insulin resistance. The invention also discloses the potential of a curcuminoid composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin for use in the therapeutic management of PCOS.

Abstract: The invention discloses a composition comprising Cyperus rotundus extract and Passiflora edulis extract comprising piceatannol, scirpusin B, scirpusin A, cyperusphenol A and cyperusphenol B, standardized to contain 6-10% w/w total stilbenes and a process of preparing the composition thereof. The invention also discloses the use of the above mentioned composition in enhancing energy expenditure in mammalian adipose cellular systems by the conversion of white adipose tissues to brown adipose tissues, inhibition of adipogenesis and for preventing weight gain in mammals.

Abstract: A composition enriched with bisdemethoxycurcumin standardized to contain 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin. More specifically the invention discloses the potential of a composition comprising 20-80% w/w bisdemethoxycurcumin, 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin in the management of nephrotoxicity in mammals. The composition further comprises a Nigella sativa extract standardised to contain not less than 2% w/w thymoquinone and about 0.01%-10% w/w thymohydroquinone.

Abstract: The present invention discloses a method of isolating secondary metabolites, specifically arjunolic acid, from the calli and/or the suspension cultures derived from the pluripotent cambium tissue of Terminalia arjuna. The invention also discloses a method of inducing callus, establishing and maintaining suspension cultures of callus derived from the cambium of Terminalia arjuna for the isolation of secondary metabolites.

Abstract: The invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of nephropathy in mammals. The composition further comprises ?-glucogallin and total mucic acid gallates, C-glucosides and tannins isolated from Pterocarpus marsupium. The invention also discloses the potential of the composition comprising ?-glucogallin and total mucic acid gallates from Emblica officinalis, C-glucosides and tannins isolated from Pterocarpus marsupium in the therapeutic management of nephropathy.

Abstract: The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises ?-amyrin palmitate (BAP). The invention also includes disclose the use of the above composition in the management of chronic inflammatory condition in a subject.

Abstract: The present invention discloses methods and compositions comprising. Andrographis paniculata extract standardized to contain not less than 10% w/w andrographolides, Polygonum cuspidatum extract standardized to contain not less than 80% w/w resveratrol, Piper nigrum extract standardized to contain 95% w/w piperine, 95% tetrahydrocurcuminoids, vitamins for the management of viral infections, specifically COVID infection. The invention also discloses the use of the compositions in preventing proteolytic activation of viral spike protein by inhibiting the furin enzyme.

Abstract: The invention discloses a composition comprising Cyperus rotundus extract and Passiflora edulis extract comprising piceatannol, scirpusin B, scirpusin A, cyperusphenol A and cyperusphenol B, standardized to contain 6-10% w/w total stilbenes. The invention also discloses the use of the above mentioned composition in enhancing energy expenditure in mammalian adipose cellular systems by the conversion of white adipose tissues to brown adipose tissues, inhibition of adipogenesis and for preventing weight gain in mammals.

Abstract: The invention discloses a composition comprising not less than 20% w/w bisdemethoxycurcumin for regeneration of alveolar cells damaged in emphysematous conditions and for the therapeutic management of chronic obstructive pulmonary disease and acute respiratory distress syndrome. The composition further comprises 10-35% w/w demethoxycurcumin and 10-45% w/w curcumin. The composition is very suitable for treating COPD and ARDS due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Abstract: Disclosed are the skin care applications of a composition containing the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856. More specifically, the invention discloses the ability of the partially purified extracellular metabolite isolated from Bacillus coagulans MTCC 5856 to confer protection to the skin fibroblasts against UV induced cell damage and apoptosis, oxidative stress and inflammation.

Abstract: The disclosed invention relates to a method comprising composition for effective management of peritonitis in a subject. The invention also discloses a method comprising composition for preventing peritonitis mediated multi organ dysfunction and management of inflammation in a subject. The composition disclosed essentially consists of Witharione.

Abstract: The present invention discloses methods and compositions for therapeutic management of obesity and high fat diet induced hyperlipidemia in mammals, using a composition comprising not less than 20% w/w bisdemethoxycurcumin, wherein the composition further comprises of 10-35% w/w demethoxycurcumin and 10-50% w/w curcumin.

Abstract: The present invention discloses a compound, Vanillylidenechloroacetone (VCA)—1-Chloro-4-(4?-hydroxy-3?-methoxy-phenyl)-but-3-en-2-one, and the process of preparing the same. The invention also discloses a process for synthesis of Calebin-A from Vanillylidenechloroacetone.

Abstract: The present invention discloses a method for therapeutic management of pulmonary fibrosis in mammals using a composition comprising iso-garcinol or octahydrocurcumin or a combination of iso-garcinol and octahydrocurcumin. The composition is very suitable for treating pulmonary fibrosis due to viral infections, specifically COVID 19 and for improving lung function during prognosis.

Abstract: The present invention discloses a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids and its therapeutic application. More specifically, the present invention discloses the use of a composition comprising 70%-80% w/w tetrahydrocurcuminoids, 10%-20% w/w hexahydrocurcuminoids and 5%-10% w/w octahydrocurcuminoids in the therapeutic management of metabolic syndrome in mammals.

Abstract: The invention discloses a composition and method for therapeutically managing a demyelinated disorder through remyelination. The invention includes a composition comprising Withaferin A and Bisdemethoxycurcumin (BDMC), and a pharmaceutically or nutraceutically acceptable excipients, which can be effectively formulated as tablets and capsules. The invention also covers use of composition for effectively managing a demyelinated disorder through remyelination.

Abstract: The present invention relates to a composition for recovering from and/or alleviating a hangover, containing Garcinia indica. The composition for recovering from and/or alleviating a hangover of the present invention has an excellent recovery and/or alleviation effect on a hangover, and thus the composition for recovering from and/or alleviating a hangover has high industrial usefulness.

Abstract: The invention discloses novel intermediates in the synthesis of Calebin A represented by formula 3. The invention also covers processes for the synthesis of Calebin-A and its analogs using compounds of formula 3.